Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

2.585 +0.025 (+0.98%)
Streaming Delayed Price Updated: 10:54 AM EDT, Apr 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MannKind Corporation - Common Stock

< Previous 1 2 3 4 Next >
News headline image
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Settlement of Convertible Senior Notes
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
News headline image
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)
Study to assess safety, efficacy and treatment experience of starting inhaled insulin in youth aged 10 to <18 years recently diagnosed with T1D 
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy
From MannKind
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
MannKind Provides Business Updates and 2026 Growth Drivers
From MannKind
Via GlobeNewswire
News headline image
MannKind Shares FUROSCIX® Business Updates
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces U.S. FDA Accepts for Review its Supplemental New Drug Application (sNDA) of FUROSCIX ReadyFlow™ Autoinjector for the Treatment of Edema in Adults with Chronic Heart Failure or Chronic Kidney Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at the Jefferies Global Healthcare Conference
From MannKind
Via GlobeNewswire
News headline image
MannKind Provides Update on Phase 3 ICoN-1 Trial of Nebulized Clofazimine for NTM Lung Disease
From MannKind
Via GlobeNewswire
News headline image
MannKind Commemorates Alfred E. Mann’s 100th Birthday with New Scholarship Program Supporting Young Adults Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
From MannKind
Via GlobeNewswire
News headline image
MannKind Completes Acquisition of scPharmaceuticals, Accelerating Revenue Growth in Cardiometabolic Care
From MannKind
Via GlobeNewswire
News headline image
MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer
From MannKind
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
Initial collaboration led to Tyvaso DPI®, the first FDA-approved dry powder inhalation treatment for pulmonary hypertension 
From MannKind
Via GlobeNewswire
News headline image
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
News headline image
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
Conference call today at 9:00 am ET 
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
From MannKind
Via GlobeNewswire
News headline image
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
From MannKind
Via GlobeNewswire
News headline image
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
News headline image
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.